Insider Buying: ChromaDex Co. (NASDAQ:CDXC) CFO Acquires 2,907 Shares of Stock

ChromaDex Co. (NASDAQ:CDXC) CFO Ozan Pamir bought 2,907 shares of the company’s stock in a transaction that occurred on Friday, November 22nd. The shares were purchased at an average price of $7.36 per share, with a total value of $21,395.52. Following the transaction, the chief financial officer now directly owns 2,907 shares in the company, valued at $21,395.52. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

ChromaDex Price Performance

CDXC stock traded up $0.03 during midday trading on Monday, reaching $7.47. The company had a trading volume of 272,374 shares, compared to its average volume of 539,281. ChromaDex Co. has a 1-year low of $1.32 and a 1-year high of $7.85. The company has a market capitalization of $570.56 million, a price-to-earnings ratio of 744.74 and a beta of 1.88. The stock has a 50 day moving average price of $4.61 and a 200-day moving average price of $3.59.

ChromaDex (NASDAQ:CDXC) last issued its quarterly earnings data on Thursday, October 31st. The company reported $0.02 EPS for the quarter. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. The business had revenue of $25.58 million during the quarter, compared to the consensus estimate of $23.70 million. During the same quarter in the prior year, the firm earned ($0.01) EPS. As a group, research analysts anticipate that ChromaDex Co. will post 0.04 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on CDXC. HC Wainwright increased their price objective on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a report on Monday, November 4th. StockNews.com lowered shares of ChromaDex from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 18th. Finally, Roth Mkm raised their target price on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th.

Institutional Investors Weigh In On ChromaDex

Large investors have recently modified their holdings of the company. SG Americas Securities LLC acquired a new stake in ChromaDex in the first quarter worth $54,000. Acadian Asset Management LLC purchased a new position in shares of ChromaDex during the first quarter valued at approximately $67,000. Lazard Asset Management LLC bought a new stake in shares of ChromaDex in the 1st quarter worth $43,000. Miracle Mile Advisors LLC purchased a new stake in ChromaDex in the 2nd quarter valued at about $27,000. Finally, Bank of New York Mellon Corp boosted its position in ChromaDex by 170.0% in the second quarter. Bank of New York Mellon Corp now owns 190,442 shares of the company’s stock worth $520,000 after purchasing an additional 119,915 shares during the last quarter. 15.41% of the stock is currently owned by institutional investors and hedge funds.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.